Researchers focused on data from nearly 78,000 adults with cardiometabolic disorders, sharing their findings at ACC.25 in Chicago.

Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.  

Powerful Medical's advanced algorithm was designed to detect STEMI and STEMI-equivalent patterns in a patient’s ECG results.

When patients require subsequent noncardiac surgery after a major heart operation, waiting at least 100 days is one way to limit the risk of an adverse event. Read the full analysis in JACC: Advances.

Abbott has received an investigational device exemption from the FDA for a new clinical trial evaluating the safety and effectiveness of using its coronary IVL technology. The trial is expected to enroll up to 335 U.S. patients.